Verastem Stock Earnings Reports

Verastem reported Q1 2026 net product revenue of $18.7M (≈$50M total since launch of the AVMAPKI FAKZYNJA CO‑PACK in May 2025). The company says launch traction is steady with >400 unique prescribers and ~65% of commercially eligible patients using its co‑pay program. Management identified seasonal headwinds (insurance reverifications, severe weather) and an early-adopter prescribing pattern (sicker patients stopping therapy sooner) as drivers of shorter‑than‑expected duration/refill patterns, but reports a rebound in new starts since January. Commercial changes include adding sales headcount, tighter follow-up between specialty pharmacy/field teams, a new CCO (Dan Lyons), and a direct physician/patient campaign to encourage earlier use at first recurrence. R&D progress centers on VS‑7375 (Target‑D program): ongoing Phase I/II (Target‑D‑101) with higher dose exploration (600 → 900 → 1,200 mg), and three Phase II registration‑directed trials in second‑line pancreatic cancer (PDAC), previously treated NSCLC, and metastatic colorectal cancer (CRC) with ORR by BICR as primary endpoints (DOR key secondary). Management believes 900 mg is the likely go‑forward dose based on PK and tolerability and is advancing combinations (notably with anti‑EGFR antibodies and chemo) to support potential accelerated approvals. Financials: Q1 R&D $38.2M, SG&A $22.3M, non‑GAAP adjusted net loss $42.7M (‑$0.43/sh). Cash, cash equivalents and investments were $181.7M at quarter end, which management says provides runway into H1 2027; they expect the LGSOC franchise to be self‑sustaining in H2 2026 with CO‑PACK revenues funding commercial ops and related trials. Key near‑term catalysts: Target‑D 101 interim update in H1 2026 (safety, PK, early cases) and more comprehensive tumor‑specific efficacy datasets in H2 2026; RAMP‑205 PDAC update expected before end of Q2. Management continues to prioritize disciplined capital management and nondilutive financing opportunities.